Citizens Jmp Issues Positive Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price

Posted by Brenda Bartman on Aug 7th, 2026

Cytokinetics (NASDAQ:CYTK – Get Free Report) had its price objective hoisted by analysts at Citizens Jmp from $105.00 to $110.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “market outperform” rating on the biopharmaceutical company’s stock. Citizens Jmp’s price objective suggests a potential upside of 44.32% from the company’s previous close.

Other research analysts also recently issued reports about the stock. Truist Financial set a $106.00 target price on shares of Cytokinetics in a research report on Tuesday, May 5th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Cytokinetics in a research note on Friday. Stifel Nicolaus lifted their target price on shares of Cytokinetics from $98.00 to $108.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. UBS Group upgraded shares of Cytokinetics from a “neutral” rating to a “buy” rating and upped their target price for the company from $69.00 to $115.00 in a research report on Monday, June 29th. Finally, JPMorgan Chase & Co. increased their price target on Cytokinetics from $92.00 to $97.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $101.10.

View Our Latest Stock Report on Cytokinetics

Cytokinetics Stock Down 6.3%

NASDAQ:CYTK traded down $5.15 on Friday, reaching $76.22. The stock had a trading volume of 1,000,844 shares, compared to its average volume of 2,162,348. The stock has a fifty day moving average price of $78.91 and a 200-day moving average price of $70.86. Cytokinetics has a 1-year low of $32.89 and a 1-year high of $88.31. The company has a market capitalization of $9.48 billion, a P/E ratio of -11.18 and a beta of 0.38.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.63) by $0.13. The company had revenue of $28.62 million during the quarter, compared to the consensus estimate of $17.59 million. The company’s revenue was down 57.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.12) earnings per share. Sell-side analysts predict that Cytokinetics will post -6.2 earnings per share for the current fiscal year.

Insider Transactions at Cytokinetics

In related news, Director B Lynne Parshall sold 5,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $74.08, for a total value of $370,400.00. Following the completion of the sale, the director directly owned 15,784 shares in the company, valued at $1,169,278.72. This represents a 24.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 7,500 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $84.92, for a total value of $636,900.00. Following the completion of the sale, the chief executive officer directly owned 377,830 shares of the company’s stock, valued at approximately $32,085,323.60. The trade was a 1.95% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 115,179 shares of company stock worth $9,126,054. Company insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Cytokinetics

Several large investors have recently added to or reduced their stakes in CYTK. Millennium Management LLC lifted its position in shares of Cytokinetics by 361.9% during the 1st quarter. Millennium Management LLC now owns 287,901 shares of the biopharmaceutical company’s stock valued at $11,571,000 after acquiring an additional 225,576 shares during the period. Cetera Investment Advisers raised its holdings in Cytokinetics by 12.4% during the second quarter. Cetera Investment Advisers now owns 6,635 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 731 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Cytokinetics by 723.7% during the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 673 shares in the last quarter. Gabelli Funds LLC raised its holdings in shares of Cytokinetics by 29.4% in the 2nd quarter. Gabelli Funds LLC now owns 8,410 shares of the biopharmaceutical company’s stock worth $278,000 after acquiring an additional 1,910 shares during the last quarter. Finally, California Public Employees Retirement System raised its stake in shares of Cytokinetics by 10.8% in the second quarter. California Public Employees Retirement System now owns 142,602 shares of the biopharmaceutical company’s stock valued at $4,712,000 after buying an additional 13,911 shares during the period.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

Positive Sentiment: Needham raised its price target to $112 and reiterated a Buy rating, implying substantial upside and reinforcing the bullish analyst view of Cytokinetics’ pipeline and long-term prospects. Benzinga analyst rating report
Positive Sentiment: For the second quarter of 2026, Cytokinetics reported a loss of $1.50 per share, narrower than the consensus loss estimate of $1.63. Revenue of $28.6 million also exceeded estimates of approximately $17.6 million. Cytokinetics second-quarter 2026 results
Neutral Sentiment: The company ended the quarter with approximately $1.17 billion in cash and equivalents, providing funding for ongoing development and commercialization efforts. However, operating cash outflow was approximately $159.8 million.
Negative Sentiment: Revenue fell 57.1% year over year, while Cytokinetics remained deeply unprofitable. The company posted a $179.2 million operating loss and a $198.8 million net loss attributable to common shareholders. Cytokinetics Q2 earnings analysis
Negative Sentiment: Reported insider activity showed 49 sales and no purchases during the past six months, including selling by senior executives. Although insider sales can reflect compensation or planned transactions, the lack of purchases may weigh on sentiment.

About Cytokinetics

(Get Free Report)

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.